| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,819 |
15,558 |
$1.23M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,079 |
6,093 |
$476K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,489 |
2,322 |
$305K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,764 |
2,637 |
$290K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,034 |
1,947 |
$239K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,331 |
1,983 |
$151K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
7,702 |
6,860 |
$82K |
| 90670 |
|
1,410 |
1,278 |
$67K |
| 87428 |
|
920 |
884 |
$57K |
| 90698 |
|
1,046 |
981 |
$26K |
| 90461 |
|
4,676 |
4,100 |
$16K |
| 90744 |
|
609 |
495 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
249 |
225 |
$14K |
| 99188 |
|
1,231 |
1,145 |
$14K |
| 99381 |
|
366 |
182 |
$13K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
763 |
688 |
$3K |
| 97802 |
|
11,096 |
9,399 |
$2K |
| 83655 |
|
284 |
269 |
$528.66 |
| 90716 |
|
631 |
589 |
$510.11 |
| 90715 |
|
875 |
710 |
$435.47 |
| 90619 |
|
135 |
130 |
$280.00 |
| 90700 |
|
1,388 |
1,177 |
$245.10 |
| 90633 |
|
543 |
516 |
$200.00 |
| 90651 |
|
628 |
583 |
$200.00 |
| 90680 |
|
742 |
698 |
$198.76 |
| 85018 |
|
429 |
404 |
$198.32 |
| 90734 |
|
504 |
451 |
$188.06 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
93 |
85 |
$155.89 |
| 90686 |
|
562 |
499 |
$77.08 |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
16 |
14 |
$51.33 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
107 |
68 |
$47.16 |
| G0306 |
Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count |
382 |
343 |
$22.07 |
| 80053 |
Comprehensive metabolic panel |
374 |
335 |
$20.25 |
| 81002 |
|
55 |
43 |
$2.09 |
| 90707 |
|
603 |
559 |
$0.00 |
| 90685 |
|
33 |
33 |
$0.00 |
| 90710 |
|
12 |
12 |
$0.00 |
| 90649 |
|
36 |
30 |
$0.00 |
| 90713 |
|
183 |
163 |
$0.00 |
| 90648 |
|
54 |
38 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
49 |
20 |
$0.00 |
| 90621 |
|
26 |
19 |
$0.00 |
| 90620 |
|
210 |
201 |
$0.00 |
| 90677 |
|
97 |
95 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
132 |
44 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26 |
14 |
$0.00 |